Empowered Patient Podcast

Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule to treat diabetic macular edema which is showing an increase in prevalence due to the increase in the number of people suffering from diabetes. Brian explains, "DME or diabetic macular edema is a complication of diabetes. It's a subset of diabetic retinopathy. And like other complications of diabetes, the blood vessels in the eye become injured or corrupted. And this leads to inflammation in the leakage of fluid across the blood vessel into the eye. And in this case, into the macula of the retina, which is responsible for high-resolution vision. If that continues, it can result in progressive visual loss and even blindness." "Another problem with these therapies is that in some patients, they